A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

Inclusion Criteria: * Adult with RA for at least 6 months * Stable weekly dosage of oral methotrexate 12.5- 25 mg/week Exclusion Criteria: * Severe, progressive and/or uncontrolled other disease * Chronic or recent serious infection; current infection * Concomitant use of RA therapy other than methotrexate with some exceptions